Inclusion Criteria:  Subjects 18 to 80 years of age, inclusive, at the time of consent Ability to provide written informed consent and to be compliant with the schedules of protocol assessments Have CD for ≥ 3 months prior to randomization, involving the ileum and/or colon, at a minimum; diagnosis may be confirmed at any time in the past by endoscopy and/or histopathology. The screening endoscopy and histopathology reports may serve as source documents for subjects who do not have diagnostic endoscopy reports in their medical chart Have moderately to severely active CD at Screening, defined as: CDAI score ≥ 220 and ≤ 450 Unweighted average worst daily AP (kg) score ≥ 2 (using a 4-point scale; ie, 0 [none] to 3 [severe]) OR unweighted average daily loose (kg)/watery SF (Bristol Stool Form Scale [BSFS] type 6 or 7) score ≥ 4 SES-CD of ≥ 6 or SES-CD ≥ 4 for subjects with isolated ileal disease, Demonstrated inadequate response, loss of response to, or intolerance to ≥ 1 of the following therapies for the treatment of CD: Oral corticosteroids (eg, prednisone [or its equivalent] or budesonide Immunosuppressants (eg, AZA, 6-mercaptopurine [6-MP], or MTX)  Exclusion Criteria:  History of inadequate response (ie, primary non-response) to agents from ≥ 2 classes of biologics marketed for the treatment of CD (ie, TNFα antagonists, interleukin-12/-23 antagonist, and integrin receptor antagonist, refer to Appendix 9) Have stopped, started, or changed the dosage of oral 5-ASA compounds ≤ 2 weeks prior to randomization or do not intend to maintain the same dose during the study 3Have stopped, started, or changed the dosage of oral corticosteroids (prednisone ≤ 20 mg/day or its equivalent, budesonide ≤ 9 mg/day) ≤ 2 weeks prior to randomization Have a confirmed ALC < 800 cells/mm3 (< 0.8 × 109 cells/L) at Screening or confirmed absolute neutrophil count < 1000 cells/mm3 (< 1.0 × 109 cells/L) at Screening Have confirmed aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN) and total bilirubin > 1.5 × ULN (unless consistent with a history of Gilbert's Syndrome) at Screening